Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome
Atherosclerosis — Nakazawa M, Arashi H, Yamaguchi J, et al. | May 19, 2020
This study was conducted to explore if high-density lipoprotein cholesterol (HDL-C) at 3-month follow-up for patients receiving contemporary lipid-lowering therapy after acute coronary syndrome (ACS) could prognosticate cardiac events. Researchers conducted the HIJ-PROPER study which was a multicenter, prospective, randomized trial comparing intensive lipid-lowering therapy (pitavastatin+ezetimibe) and conventional lipid-lowering therapy (pitavastatin monotherapy) after ACS. According to tertiles of HDL-C levels at 3-month follow-up, the entire cohort was classified into three groups (Group 1, HDL-C ≤ 43 mg/dL; Group 2, HDL-C >43, < 53.6 mg/dL; Group 3; HDL-C ≥53.6 mg/dL). At 3-month follow-up, lower levels of HDL-C are independently correlated with higher incidence of cardiovascular events in ACS patients receiving contemporary lipid-lowering therapy.